U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562074) titled 'Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis' on Jan. 06.
Brief Summary: Canada has one of the highest rates of multiple sclerosis (MS). MS patients experience disabling motor, visual, and sensory symptoms, and a high risk of comorbid major depressive disorder (MDD) and severe fatigue. The lifetime prevalence of MDD in MS patients is about 50%, and nearly 90% experience severe fatigue, both of which are not responsive to typical treatments. Repetitive transcranial magnetic stimulation (rTMS) is a first line, Health Canada approved non-invasive neurostimulation treatment for MDD. rTMS induces electrical activi...